What is Zacks Research’s Estimate for FOLD Q3 Earnings?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Research analysts at Zacks Research raised their Q3 2025 EPS estimates for shares of Amicus Therapeutics in a note issued to investors on Wednesday, October 16th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings per share of $0.04 for the quarter, up from their prior forecast of $0.03. The consensus estimate for Amicus Therapeutics’ current full-year earnings is ($0.07) per share. Zacks Research also issued estimates for Amicus Therapeutics’ FY2025 earnings at $0.14 EPS.

Other equities research analysts have also issued research reports about the stock. Bank of America lifted their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday. Morgan Stanley reduced their price objective on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. JPMorgan Chase & Co. cut their target price on shares of Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a research report on Friday, August 16th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research report on Friday, August 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $20.00 target price on shares of Amicus Therapeutics in a research report on Friday, September 20th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, Amicus Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $17.13.

Amicus Therapeutics Stock Down 0.6 %

FOLD stock opened at $11.90 on Friday. The company has a current ratio of 2.75, a quick ratio of 2.26 and a debt-to-equity ratio of 2.93. Amicus Therapeutics has a 1 year low of $9.02 and a 1 year high of $14.57. The company has a fifty day simple moving average of $11.17 and a 200 day simple moving average of $10.56. The firm has a market cap of $3.52 billion, a PE ratio of -24.29 and a beta of 0.69.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The business had revenue of $126.67 million during the quarter, compared to analyst estimates of $121.21 million. During the same quarter in the previous year, the business earned ($0.15) EPS. Amicus Therapeutics’s quarterly revenue was up 34.0% compared to the same quarter last year.

Insider Transactions at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $11.71, for a total transaction of $87,825.00. Following the transaction, the chief executive officer now owns 886,654 shares in the company, valued at approximately $10,382,718.34. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders have sold 22,500 shares of company stock worth $244,875. 2.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in FOLD. Blue Trust Inc. increased its stake in Amicus Therapeutics by 1,705.4% in the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 2,831 shares during the period. Headlands Technologies LLC bought a new stake in Amicus Therapeutics in the second quarter valued at about $89,000. Sage Capital Advisors llc bought a new stake in Amicus Therapeutics in the second quarter valued at about $103,000. Sanctuary Advisors LLC bought a new stake in Amicus Therapeutics in the second quarter valued at about $138,000. Finally, EntryPoint Capital LLC increased its stake in Amicus Therapeutics by 278.8% in the first quarter. EntryPoint Capital LLC now owns 13,218 shares of the biopharmaceutical company’s stock valued at $156,000 after acquiring an additional 9,729 shares during the period.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.